Anjali Narayan Avadhani

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

Yohann Loriot, Andrea Necchi, Se Hoon Park et al. · New England Journal of Medicine · 2019 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +15

First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and <i>FGFR</i> alterations (FGFRalt).

Arlene O. Siefker‐Radtke, Andrea Necchi, Se Hoon Park et al. · Journal of Clinical Oncology · 2018 · 73 citations

Medicine, Oncology, Pharmacology +15

Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and <i>FGFR</i> alterations (FGFRa): Phase 2 continuous versus intermittent dosing.

Yohann Loriot, Andrea Necchi, Se Hoon Park et al. · Journal of Clinical Oncology · 2018 · 28 citations

Medicine, Oncology, Pharmacology +14

Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer

Christine Ciunci, Rodolfo F. Perini, Anjali Narayan Avadhani et al. · Cancer · 2013 · 24 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy of programmed death 1 (PD-1) and programmed death 1 ligand (PD-L1) inhibitors in patients with <i>FGFR</i> mutations and gene fusions: Results from a data analysis of an ongoing phase 2 study of erdafitinib (JNJ-42756493) in patients (pts) with advanced urothelial cancer (UC).

Arlene O. Siefker‐Radtke, Andrea Necchi, Eli Rosenbaum et al. · Journal of Clinical Oncology · 2018 · 16 citations

Medicine, Immunology, Oncology +17